Read more
3:33 PM · 15 March 2024

Geron surges almost 100% after FDA vote

-
-
Open account Download free app

Geron (GERN.US), US biotechnology company, is surging almost 100% today! Share price surge comes in response to US Food and Drug Administration (FDA) advisory panel approving company's anemia drug candidate, Imetelstat. FDA panel voted 12-2 in favor of the drug, saying that its benefits of Imetelstat outweigh risks for the targeted patient population. While final approval from FDA is expected by June 16, 2024, FDA often follows recommendations of advisory panels.

While FDA is not obliged to follow advisory panel recommendations, a strongly positive 12-2 vote results shows that there is a very high chance of regulatory approval in June.

Taking a look at Geron chart (GERN.US) at D1 interval, we can see that today's surge is indeed massive. Stock bounced off the $1.70 support zone and rallied to the highest level since mid-June 2023. Advance has been halted at the $3.40 resistance zone, marked with local highs from the first half of 2023. Nevertheless, even after today's surge the stock is trading over 50% below its all-time highs from September 2018.

Source: xStation5

11 February 2026, 3:17 PM

Palo Alto acquires CyberArk. A new leader in cybersecurity!

11 February 2026, 2:44 PM

US OPEN: Blowout Payrolls Signal Slower Path for Rate Cuts?

11 February 2026, 1:15 PM

Market wrap: Oil gains amid US - Iran tensions 📈 European indices muted before US NFP report

11 February 2026, 8:30 AM

Economic calendar: NFP data and US oil inventory report 💡

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits